Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.
Martin J. van den Bent(Erasmus MC Cancer Institute), Pim J. French(Erasmus MC Cancer Institute), Anna K. Nowak(The University of Western Australia), Michael Weller(University Hospital of Zurich), Jean‐François Baurain(Cliniques Universitaires Saint-Luc), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Pieter Wesseling(Radboud University Nijmegen), Sara Erridge(The University of Texas MD Anderson Cancer Center), Mircea Tesileanu(Erasmus MC Cancer Institute), Kenneth Aldape(National Institutes of Health), Marc Sanson(Centre National de la Recherche Scientifique), Johan M. Kros(Erasmus MC), Brigitta G. Baumert(Kantonsspital Graubünden), Helen Wheeler(The University of Sydney), Wolfgang Wick(German Cancer Research Center), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Vassilis Golfinopoulos(Champalimaud Foundation), Paul M. Clément(Universitair Ziekenhuis Leuven), Michael A. Vogelbaum(Moffitt Cancer Center), Warren Mason(Princess Margaret Cancer Centre)
Cited by 48
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Paraneoplastic anti– <i>N</i> ‐methyl‐ <scp>D</scp> ‐aspartate receptor encephalitis associated with ovarian teratoma
|Annals of Neurology|2007|2.5k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k